A Bioreactor for 3D
bioreactor 3D cell culture
mechanotrasduction
osteoblast (OB)
osteocyte
prostate cancer
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
10
2021
accepted:
04
03
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
The bone is a mechanosensitive organ that is also a common metastatic site for prostate cancer. However, the mechanism by which the tumor interacts with the bone microenvironment to further promote disease progression remains to be fully understood. This is largely due to a lack of physiological yet user-friendly models that limit our ability to perform in-depth mechanistic studies. Here, we report a tunable bioreactor which facilitates the 3D culture of the osteocyte cell line, MLO-Y4, in a hydroxyapatite/tricalcium phosphate (HA/TCP) scaffold under constant fluidic shear stress and tunable hydrostatic pressure within physiological parameters. Increasing hydrostatic pressure was sufficient to induce a change in the expression of several bone remodeling genes such as Dmp1, Rankl, and Runx2. Furthermore, increased hydrostatic pressure induced the osteocytes to promote the differentiation of the murine macrophage cell line RAW264.7 toward osteoclast-like cells. These results demonstrate that the bioreactor recapitulates the mechanotransduction response of osteocytes to pressure including the measurement of their functional ability in a 3D environment. In conclusion, the bioreactor would be useful for exploring the mechanisms of osteocytes in bone health and disease.
Identifiants
pubmed: 35402411
doi: 10.3389/fbioe.2022.797542
pii: 797542
pmc: PMC8990130
doi:
Types de publication
Journal Article
Langues
eng
Pagination
797542Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM145304
Pays : United States
Informations de copyright
Copyright © 2022 Aw Yong, Horst, Neale, Royzenblat, Lahann, Greineder, Weivoda, Mehta and Keller.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Mater Chem B. 2015 May 7;3(17):3625-3633
pubmed: 26417448
Bone. 2010 Jun;46(6):1508-15
pubmed: 20211285
J Bone Miner Res. 2001 Nov;16(11):2017-26
pubmed: 11697797
Bone. 2017 Dec;105:245-252
pubmed: 28942121
Bone Res. 2015 Sep 15;3:15026
pubmed: 26421212
Biotechnol Bioeng. 2019 Nov;116(11):3084-3097
pubmed: 31317530
Hum Pathol. 2000 May;31(5):578-83
pubmed: 10836297
Nat Rev Cancer. 2005 Jan;5(1):21-8
pubmed: 15630412
Bone. 2017 Mar;96:45-50
pubmed: 27888056
Cancer Res. 2015 Jun 1;75(11):2151-8
pubmed: 25855383
Sci Rep. 2018 Dec 19;8(1):17975
pubmed: 30568232
Tissue Eng Part B Rev. 2010 Dec;16(6):587-601
pubmed: 20799909
J Biomech. 1994 Mar;27(3):339-60
pubmed: 8051194
J Cell Physiol. 1995 Apr;163(1):115-9
pubmed: 7896887
FASEB J. 2005 Mar;19(3):482-4
pubmed: 15625080
Eur Cell Mater. 2012 Aug 03;24:162-74
pubmed: 22865228
Am J Physiol. 1997 Sep;273(3 Pt 1):C810-5
pubmed: 9316399
Biofactors. 2010 Jan-Feb;36(1):25-32
pubmed: 20087883
Bone Joint Res. 2020 May 16;9(1):1-14
pubmed: 32435450
Med Sci Monit Basic Res. 2016 Sep 26;22:95-106
pubmed: 27667570
Biochem Biophys Res Commun. 1995 Dec 14;217(2):640-8
pubmed: 7503746
Curr Mol Med. 2013 May;13(4):626-39
pubmed: 23061677
PLoS One. 2012;7(3):e33336
pubmed: 22413015
Nat Med. 2011 Sep 11;17(10):1231-4
pubmed: 21909105
J Bone Miner Res. 1997 Dec;12(12):2014-23
pubmed: 9421234
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2488-93
pubmed: 16477044
Bone. 2010 May;46(5):1449-56
pubmed: 20149907
J Musculoskelet Neuronal Interact. 2016 Sep 07;16(3):221-36
pubmed: 27609037
Biochem Biophys Res Commun. 2011 Aug 19;412(1):182-7
pubmed: 21810408
Bone. 2006 Sep;39(3):565-72
pubmed: 16677866